Acoramidis reduces all-cause mortality (ACM) and cardiovascular-related hospitalization (CVH): initial outcomes from the ATTRibute-CM open-label extension (OLE) study

Daniel P Judge, Julian D Gillmore, Kevin Alexander, Amrut V Ambardekar, Francesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia, Martha Grogan, Mazen Hanna, Ahmad Masri, Laura Obici, Steen Hvitfeldt Poulsen, Nitasha Sarswat, Keyur Shah, Prem Soman, Xiaofan Cao, Kevin Wang, Maria Lucia Pecoraro, Jean-François Tamby, Leonid Katz, Jonathan C Fox, Mathew S Maurer

Click the link below to download a PDF copy of the Plain Language Summary of this presentation.

Click the link below to download a PDF copy of the presentation slides.

Click the link below to access the simultaneous publication in Circulation.

Judge D, et al. Presented at the American Heart Association meeting, November 16-18, 2024; Chicago, IL, USA

Copies of this presentation and associated educational materials obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from AHA, the authors of this poster, and the sponsor of the study (BridgeBio Pharma, Inc.).